ASMPT (00522.HK) -5.650 (-6.420%) Short selling $218.03M; Ratio 18.607% reported weaker-than-expected 2Q24 results, and guided a 6.4% QoQ decline in 3Q24 revenue, missing the expectations of Morgan Stanley/ the market by 17%/ 20% respectively, Morgan Stanley issued a research report saying.
Morgan Stanley had previously expected a modest recovery in the mainstream market, but now it looks like the weakness could last longer than expected, especially in markets outside China.
Related NewsASMPT Interim NP $315M, Down 49.6%; Interim Div. $35 Cents
Morgan Stanley kept rating at Overweight on ASMPT, with a target price of $130, saying that the stock's sell-off is an attractive market entry opportunity. The broker expected a seasonal recovery in 4Q24.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2024-07-24 16:25.)
AAStocks Financial News
China's assets explosion and the high record global capital influx hit
Hong Kong Stocks Surge, Hang Seng Index Opens Up 543 Points
China's bailout policy triggers LVMH and Hermès to rise nearly 10%
Will policies boost confidence and the A-share market live up to expectations?
Check whenever you want
WikiStock APP